PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1837-1847

  Wang, Guihua ^a   Yang, Xi ^a   Li, Chuan ^a   Cao, Xiaonian ^a   Luo, Xuelai ^a   Hu, Junbo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; PIK3R3 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; METASTATIC COLORECTAL CANCER; ONCOGENE; PIK3R3 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; TUMOR INVASION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLORECTAL TUMOR; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HCT116 CELLS; HETEROGRAFTS; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84904204581     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0049     Document Type: Article

References (37)

1. Tamaki M, Maeda S, Deguchi T, Kawada Y. Usefulness of DNA ploidy, AgNORs, PCNA and c-erbB-2 as predictors of prognosis in patients with renal cell carcinoma. Hinyokika Kiyo 1997;43:697-702. (Pubitemid 127509307)
2. Beltrami CA, Di Loreto C, Finato N, Rocco M, Artico D, Cigola E, et al. Proliferating cell nuclear antigen (PCNA), DNA synthesis and mitosis in myocytes following cardiac transplantation in man. J Mol Cell Cardiol 1997;29:2789-802. (Pubitemid 27466501)
3. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
4. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
5. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
6. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010;107:11381-6.
7. Backer JM. The Regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol 2011;346:87-114.
8. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ 2005;12:1578-87. (Pubitemid 41679163)
9. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
10. Thiele J, Zirbes TK, Bertsch HP, Titius BR, Lorenzen J, Fischer R. AIDS-related bone marrow lesions-myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Anal Cell Pathol 1996;11:141-57. (Pubitemid 26289003)
11. Tratner I, Piard K, Grenon M, Perderiset M, Baldacci G. PCNA and DNA polymerase delta catalytic subunit from Schizosaccharomyces pombe do not interact directly. Biochem Biophys Res Commun 1997;231:321-8. (Pubitemid 27214305)
12. Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010;11:615-28.
13. Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, et al. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995;15:4453-65.
14. Xia X, Cheng A, Akinmade D, Hamburger AW. The N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol Cell Biol 2003;23:1717-25. (Pubitemid 36246052)
15. Miura M, Nakamura S, Sasaki T, Takasaki Y, Shiomi T, Yamaizumi M. Roles of XPG and XPF/ERCC1 endonucleases in UV-induced immunostaining of PCNA in fibroblasts. Exp Cell Res 1996;226:126-32. (Pubitemid 26238935)
16. Hutton RD, Roberts JA, Penedo JC, White MF. PCNA stimulates catalysis by structure-specific nucleases using two distinct mechanisms: substrate targeting and catalytic step. Nucleic Acids Res 2008;36:6720-7.
17. Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, et al. Apeptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther 2008;7:3719-28.
18. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, et al. Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007;13:5314-21. (Pubitemid 47510355)
19. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, et al. Elevated expression of thymosin beta4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1alpha in early-stage cervical cancers. Pathol Oncol Res 2011;17:493-502.
20. Altavilla G, Marchetti M, Padovan P, Marcato E, Onnis A. Predictive value of proliferative cellular nuclear antigen (PCNA) and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer. Eur J Gynaecol Oncol 1996;17:524-8. (Pubitemid 26413761)
21. Toth DP, Guenther LC, Shum DT. Proliferating cell nuclear antigen (PCNA); prognostic value in the clinical recurrence of primary basal cell carcinoma. J Dermatol Sci 1996;11:36-40. (Pubitemid 26040550)
22. Baez A, Torres K, Tan EM, Pommier Y, Casiano CA. Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Cell Prolif 1996;29:183-96.
23. Wang G, Deng Y, Cao X, Lai S, Tong Y, Luo X, et al. Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells. Cell Death Differ 2012;19:1870-9.
24. Ow KT, Mameghan H, Lochhead A, Fisher R, Yang JL, Mameghan J, et al. The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localized human prostatic adenocarcinoma. Urol Oncol 1995;1:144-52.
25. Qiao B, Yu S, Pang S. Proliferating cell nuclear antigen (PCNA) in oral leukoplakia. Zhonghua Kou Qiang Yi Xue Za Zhi 1995;30:210-1.
26. Tsuji T, Mimura Y, Wen S, Li X, Kanekawa A, Sasaki K, et al. The significance of PCNA and p53 protein in some oral tumors. Int J Oral Maxillofac Surg 1995;24:221-5.
27. Shivji MK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr Biol 1994;4:1062-8. (Pubitemid 124001592)
28. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE, et al. Proliferating cell nuclear antigen (PCNA) immunostaining - a prognostic factor in ovarian cancer? Br J Cancer 1995;71:357-62.
29. Xia X, Serrero G. Multiple forms of p55PIK, a regulatory subunit of phosphoinositide 3-kinase, are generated by alternative initiation of translation. Biochem J 1999;341:831-7. (Pubitemid 29389217)
30. Acharya N, Yoon JH, Gali H, Unk I, Haracska L, Johnson RE, et al. Roles of PCNA-binding and ubiquitin-binding domains in human DNA polymerase eta in translesion DNA synthesis. Proc Natl Acad Sci U S A 2008;105:17724-9.
31. Demirtas E, Yilmaz F, Ovul I, Oner K. Recurrence of meningiomas versus proliferating cell nuclear antigen (PCNA) positivity and AgNOR counting. Acta Neurochir (Wien) 1996;138:1456-63. (Pubitemid 27010697)
32. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-82.
33. McNeal JE, Haillot O, Yemoto C. Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 1995;27:258-68.
34. Charollais RH, Surmacz E, Baserga R. Introns determine the time of appearance of PCNA mRNA in 3T3 cells stimulated by growth factors. Biochem Biophys Res Commun 1994;201:841-7.
35. Renedo DE, Trainer TD. Intratubular germ cell neoplasia (ITGCN) with p53 and PCNA expression and adjacent mature teratoma in an infant testis. An immunohistochemical and morphologic study with a review of the literature. Am J Surg Pathol 1994;18:947-52. (Pubitemid 24260235)
36. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013;31:4297-305.
37. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.